Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for Bone Erosion Repair in Rheumatoid Arthritis
NCT05955066Phase 4Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Dec 2023
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of baricitinib in rheumatoid arthritis (RA), sponsored by The Chinese University of Hong Kong. Started Dec 2023; status: recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05955066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955066.